Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a non-interventional ...

BioMarin Pharmaceutical BMRN reported third-quarter 2025 adjusted earnings per share (EPS) of 12 cents against the Zacks ...

Q3 2025 Earnings Call Transcript October 27, 2025 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS ...

How severe should myopia be in a pediatric patient to justify starting treatment, and when is it appropriate to begin ...

With an increasing number of available drugs along with a focus on early treatment regimens and drug sequencing in Crohn's disease, data from prospective, well designed studies to guide on drug choice ...

Secondary endpoints “indicate symptom reduction and patient benefit beyond improvement in disease activity,” according to ...

BioMarin will host a conference call and webcast to discuss third quarter 2025 financial results today, Monday, October 27, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on ...

Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook 2025 Year-to-date Total Revenues Increased 11% Y/Y Led by More Than ...

Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid ...